---
title: "Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference | VRCA Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287918764.md"
description: "Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) will present at the Jefferies Global Healthcare Conference on June 4, 2026, at 11:05 am ET. CEO Jayson Rieger will discuss the company's dermatological treatments, including the FDA-approved YCANTH® for molluscum contagiosum. A live webcast will be available, with a replay accessible for 90 days post-event."
datetime: "2026-05-28T04:05:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287918764.md)
  - [en](https://longbridge.com/en/news/287918764.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287918764.md)
generator: "portal-rs"
---

# Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference | VRCA Stock News

WEST CHESTER, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference.

**Jefferies Global Healthcare Conference, June 2-4, 2026**  
**Event details:**  
Date: Thursday, June 4, 2026  
Time: 11:05am ET  
Location: New York

Participants may access a live webcast of the event by clicking the link here.

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.

**About Verrica Pharmaceuticals Inc.**  
Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.

**FOR MORE INFORMATION, PLEASE CONTACT:**  
Investors:

**John J Kirby**  
Interim Chief Financial Officer  
jkirby@verrica.com

**Kevin Gardner**  
LifeSci Advisors  
kgardner@lifesciadvisors.com

### Related Stocks

- [VRCA.US](https://longbridge.com/en/quote/VRCA.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)

## Related News & Research

- [Verrica completes enrollment in Phase 3 COVE-2 trial of YCANTH for common warts, sees data in Q1 2027](https://longbridge.com/en/news/297181851.md)
- [Grupa Azoty announces extraordinary shareholder meeting](https://longbridge.com/en/news/297635728.md)
- [“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z](https://longbridge.com/en/news/297407072.md)
- [Verrica signs exclusive deal with Medomie to market Ycanth in Israel](https://longbridge.com/en/news/293338821.md)
- [EverGen Infrastructure Reports Q2 2026 Results | EVGIF Stock News](https://longbridge.com/en/news/297122882.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**